✨ Free AI Report
Silence Therapeutics plc: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Silence Therapeutics plc
Company Research

Silence Therapeutics plc: Business Overview, Financials & Competitive Analysis

Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfe...

Analyst-debate audio for Silence Therapeutics plc

AskCyborg analysts argue the bull and bear cases for Silence Therapeutics plc across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

siRNA platform with meaningful partnerships and Phase II validation offers growth potential, but clinical-stage risk profile...

Read the full analyst-debate transcript →
Industry Biotechnology - RNA Therapeutics / Genetic Medicine
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Silence Therapeutics plc Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Silence Therapeutics plc Overview

Pro stress-test →

Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. The company leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease-associated genes in the liver.

Strategic Profile

Pro stress-test →

Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. The company has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs.

Competitive Landscape

Pro stress-test →

Silence Therapeutics is a biotechnology company and leader dedicated in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company competes in the siRNA therapeutic space alongside other RNAi developers and traditional pharma, differentiated by its proprietary mRNA GOLD platform and delivery technology. Strategic partnerships with major pharma like AstraZeneca enhance competitive positioning.

Industry Context

Silence Therapeutics plc operates in Biotechnology - RNA Therapeutics / Genetic Medicine.

Key facts

Founded: 1994 · Headquarters: London, United Kingdom · Market cap: $287M (as of March 2026)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Silence Therapeutics plc.

  • Lead program Zerlasiran (SLN360) in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a)
  • Strategic partnership with AstraZeneca for siRNA therapeutics across cardiovascular, renal, metabolic, and respiratory disease areas
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2025Q4 2024 earnings call conducted with recent Phase 2 ALPACAR-360 study data for zerlasiran in ASCVD patients
  • September 2025Presentation at Morgan Stanley 23rd Annual Global Healthcare Conference
  • +1 moreTrack every material event for Silence Therapeutics plc as it happens. Explore monitoring →
Get alerted when Silence Therapeutics plc has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Antisense/siRNA therapeuticsLeading antisense and siRNA therapeutic developer→siRNA therapeutic platformRNA therapeutics and delivery platform developer→Cardiovascular therapeuticsPharma partner on Silence's cardiovascular program expansion→

Compare Silence Therapeutics plc with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Silence Therapeutics plc operates in Biotechnology - RNA Therapeutics / Genetic Medicine. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - RNA Therapeutics / Genetic Medicine research →
NEW · MCP server

Ask your AI assistant about Silence Therapeutics plc

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Silence Therapeutics plc and its top competitor on Cyborg Score”
“What did Silence Therapeutics plc do this quarter?”
“Is Silence Therapeutics plc a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Silence Therapeutics plc do?+
Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfe...
What is Silence Therapeutics plc's Cyborg Score?+
Silence Therapeutics plc has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Silence Therapeutics plc's main competitors?+
Named competitors include Antisense/siRNA therapeutics, siRNA therapeutic platform, Cardiovascular therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Silence Therapeutics plc research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Silence Therapeutics plc research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Silence Therapeutics plc over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.